Acarix AB has the GF Score of 44, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Acarix AB
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Acarix AB (FRA:7AC) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Acarix AB GF Score Related Terms
FRA:7AC vs ABT, SYK, MDT: GF Score Comparison
For the Medical Devices subindustry, Acarix AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's GF Score distribution charts can be found below:
* The bar in red indicates where Acarix AB's GF Score falls into.
Acarix AB (FRA:7AC) has a GF Score of 44 as of Jul. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Acarix AB and its competitors. This is 26% above median its historical median of 35.00. Over the past decade, Acarix AB's GF Score has ranged from 8.00 to 52.00.
Is Acarix AB's GF Score too high?
Acarix AB's current GF Score of 44 is 26% above median its 10-year median of 35.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 52.00. Overall, Acarix AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's GF Score compare to ABT and SYK?
Acarix AB's GF Score of 44 can be compared against companies in the Medical Devices & Instruments industry. Historically, Acarix AB's own GF Score has ranged from 8.00 to 52.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Acarix AB and its competitors. Acarix AB's current GF Score is 44, which is 26% above median its own 10-year median of 35.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Acarix AB (FRA:7AC) has a current GF Score of 44. The stock's GF Value™ is €0.01, compared to a current price of €0.02 — trading 58% above its estimated fair value. The current GF Score is 44, which is 26% above median its 10-year median of 35.00. Acarix AB's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Acarix AB (FRA:7AC), the current GF Score is 44 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (FRA:7AC) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of €0.02 is trading 58% above its estimated GF Value™ of €0.01.
Key valuation signals for FRA:7AC:
GF Score: 44 (26% above median its 10-year median of 35.00)
GF Value™: €0.01 vs. price of €0.02 (58% above fair value)
No single metric tells the full story. See the FRA:7AC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score
Get the complete analysis for FRA:7AC
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7AC has been successfully added to your 